Sun Yan, Chen Tao-yang, Lu Pei-xin, Wang Jin-bing, Wu Yan, Zhang Qi-nan, Qian Geng-sun, Tu Hong
Department of Etiology, Qidong Liver Cancer Institute, Jiangsu, China.
Zhonghua Yi Xue Za Zhi. 2012 Jul 17;92(27):1874-7.
To explore the relationship between serum HBV DNA load and hepatocellular carcinogenesis in Qidong HBsAg carriers.
In 1997, 477 HBsAg carriers and 477 age, gender and residence matched HBsAg negative controls were enrolled as a prospective cohort in Qidong city. The entry serum samples were detected for the levels of HBeAg and HBV DNA. The relationship between baseline HBV DNA load and hepatocellular carcinoma (HCC) during the follow-up period from June 1997 to June 2011 were analyzed.
The total observed person-years (PY) were 12 200. Eighty-seven patients developed HCC with an incidence of 1498/100 000 PY in the HBsAg positive group versus 6 with an incidence of 94/100 000 PY (P = 0.000) in the HBsAg negative group. The relative risk (RR) was 15.96. N o significant difference existed between the incidences of other tumors in two groups (P = 0.161). Compared with the HBsAg negative group, the RR of HCC was 11.38 (95%CI 4.87 - 26.62, P < 0.01)in the HBsAg+/HBeAg- group and 29.08 (95%CI 12.37 - 68.37, P < 0.01) in the HBsAg+/HBeAg+ group; 5.80 (95%CI 2.29 - 14.70, P < 0.01) in the HBsAg+/HBV DNA- group and 27.75 (95%CI 12.07 - 63.81, P < 0.01) in the HBsAg+/HBV DNA+ group. In HBsAg positive subjects, while the HBV DNA load was classified into 5 levels namely 250 - 10(4), 10(4)-, 10(5)-, 10(6)- and ≥ 10(7) copies/ml, the relative risks for HCC at each level were 2.84 (95%CI 1.44 - 5.61, P < 0.01), 5.75 (95%CI 2.77 - 11.95, P < 0.01), 9.05 (95%CI 4.71 - 17.41, P < 0.01), 6.39 (95%CI 2.79 - 14.64, P < 0.01) and 4.35 (95%CI 2.21 - 8.56, P < 0.01) respectively versus the < 250 copies/ml group.
HBV DNA is an important risk predictor of hepatocellular carcinoma. The HBsAg carriers with the serum loads of HBV DNA between 10(5) - 10(6) copies/ml are most likely to present with HCC.
探讨启东乙肝表面抗原(HBsAg)携带者血清乙肝病毒脱氧核糖核酸(HBV DNA)载量与肝细胞癌发生之间的关系。
1997年,477名HBsAg携带者以及477名年龄、性别和居住地相匹配的HBsAg阴性对照者作为前瞻性队列纳入启东市研究。对入组时的血清样本检测乙肝e抗原(HBeAg)和HBV DNA水平。分析1997年6月至2011年6月随访期间基线HBV DNA载量与肝细胞癌(HCC)之间的关系。
总观察人年数(PY)为12200。HBsAg阳性组87例患者发生HCC,发病率为1498/100000 PY,而HBsAg阴性组6例,发病率为94/100000 PY(P = 0.000)。相对危险度(RR)为15.96。两组其他肿瘤发病率无显著差异(P = 0.161)。与HBsAg阴性组相比,HBsAg阳性/HBeAg阴性组HCC的RR为11.38(95%可信区间[CI] 4.87 - 26.62,P < 0.01),HBsAg阳性/HBeAg阳性组为29.08(95%CI 12.37 - 68.37,P < 0.01);HBsAg阳性/HBV DNA阴性组为5.80(95%CI 2.29 - 14.70,P < 0.01),HBsAg阳性/HBV DNA阳性组为27.75(95%CI 12.07 - 6?81,P < 0.01)。在HBsAg阳性受试者中,当HBV DNA载量分为250 - 10⁴、10⁴ - 、10⁵ - 、10⁶ - 和≥10⁷拷贝/毫升5个水平时,各水平HCC的相对危险度分别为2.84(95%CI?44 - 5.61,P < 0.01)、5.75(95%CI 2.77 -?95,P < 0.01)、9.05(95%CI 4.71 - 17.41,P < 0.01)、6.39(95%CI 2.79 - 14.64,P < 0.01)和4.35(95%CI 2.21 - 8.56,P < 0.01),与<250拷贝/毫升组相比。
HBV DNA是肝细胞癌的重要风险预测指标。血清HBV DNA载量在10⁵ - 10⁶拷贝/毫升之间的HBsAg携带者最易发生HCC。